Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Complement C1 esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) that regulates the activation of the complement and contact systems. It inhibits C1r and C1s in the classical complement pathway, as well as plasma kallikrein, factor XIIa, and factor XIa in the contact system. Deficiency or dysfunction of C1-INH leads to hereditary angioedema (HAE), characterized by recurrent episodes of severe swelling. Recombinant and plasma-derived C1-INH products are used therapeutically to treat and prevent HAE attacks.
Irreversible binding and inactivation of target serine proteases (C1s, kallikrein, factor XIIa, XIa) to prevent excessive activation of complement and contact systems.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Complement C1 esterase inhibitor (C1-INH).